Lawrence Fong, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Lawrence Fong, MD

Professor, Department of Medicine (Hematology/Oncology), UCSF

Phone: (415) 353-7171 (appts)
Box 0511, UCSF
San Francisco, CA 94143-0511

View on UCSF Profiles

Research Summary

I have focused on cancer immunotherapy throughout my career. After completing Oncology Fellowship at Stanford, I complete post-doctoral training with Drs. Ed Engleman and Mark Davis focused on tumor immunology. I then began my independent research program at UCSF and have continued to focus on how the immune system interacts with cancer as well as developing tumor immunotherapies in both mouse models and in patients. We described the immunogenicity of prostate acid phosphatase (PAP), which is the target antigen for sipuleucel-T, now an FDA-approved immunotherapy for prostate cancer. We were also involved with the first-in-man clinical trials with ipilimumab, an anti-CTLA4 antibody that is now FDA approved for melanoma. We continue to investigate how immunotherapies such as immune checkpoint inhibitors and cancer vaccines can enhance anti-tumor immunity in patients. I have also served on multiple NIH study sections and on the NCI Steering Committees for Genitourinary Cancer (GUSC) and Investigational Drugs (IDSC)-Immunotherapy Task Force. I have also served on the program committees for ASCO and AACR and on faculty for the AACR/ASCO Vail Methods in Clinical Research Workshop. I am the site PI at UCSF for the NCI-sponsored Cancer Immunotherapy Trials Network (CITN).

Education

Columbia University, New York, NY, BA, 1984-1988, Pre-Med., Economics
Stanford University, Stanford, CA, MD, 1988-1992


Professional Experience

  • 1992-1993
    Intern in Internal Medicine, University of Washington Medical Center.
  • 1993-1994
    Resident in Internal Medicine, University of Washington Medical Center.
  • 1994-1997
    Fellow in Medical Oncology, Stanford University School of Medicine.
  • 1996-2001
    Post-Doctoral Fellow, Department of Pathology, Stanford University School of Medicine. Mentor: Edgar Engleman, MD.
  • 1997-2002
    Staff Physician, Division of Medical Oncology, Stanford University School of Medicine.
  • 2001-2002
    Acting Assistant Professor, Department of Pathology, Stanford University School of Medicine. Mentor: Mark M. Davis, PhD
  • 2002-2008
    Assistant Professor in Residence, Department of Medicine, Division of Hematology/Oncology, University of California, San Francisco.
  • 2008-2013
    Associate Professor, Department of Medicine, Division of Hematology/Oncology, University of California, San Francisco.
  • 2013-present
    Professor, Department of Medicine, Division of Hematology/Oncology, University of California, San Francisco.

 

Honors & Awards

  • 1990
    Stanford Alumni Medical Scholar
  • 1993
    Alpha Omega Alpha
  • 1997
    American Society of Clinical Oncology Young Investigator Award
  • 1997
    American Cancer Society Post-Doctoral Fellowship Award
  • 1997
    American Association for Cancer Research AFLAC Award
  • 2002
    American Association for Cancer Research Scholar-in-Training Award
  • 2003
    V Foundation Scholar

Selected Publications

  1. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions. Expert Rev Vaccines. 2015 Dec; 14(12):1529-41.
    View on PubMed
  2. On the Verge: Immunotherapy for Colorectal Carcinoma. J Natl Compr Canc Netw. 2015 Aug; 13(8):970-8.
    View on PubMed
  3. Transglutaminase 4 as a prostate autoantigen in male subfertility. Sci Transl Med. 2015 Jun 17; 7(292):292ra101.
    View on PubMed
  4. Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab. Cancer Immunol Res. 2015 Sep; 3(9):1008-16.
    View on PubMed
  5. A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2015 Sep 1; 21(17):3862-9.
    View on PubMed
  6. Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Cancer Res. 2014 Dec 15; 20(24):6269-76.
    View on PubMed
  7. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst. 2014 Nov; 106(11).
    View on PubMed
  8. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci Transl Med. 2014 May 28; 6(238):238ra70.
    View on PubMed
  9. Enhancement of an anti-tumor immune response by transient blockade of central T cell tolerance. J Exp Med. 2014 May 5; 211(5):761-8.
    View on PubMed
  10. The end of the beginning: circulating tumor cells as a biomarker in castration-resistant prostate cancer. J Clin Oncol. 2014 Apr 10; 32(11):1104-6.
    View on PubMed
  11. Beyond sipuleucel-T: immune approaches to treating prostate cancer. Curr Treat Options Oncol. 2014 Mar; 15(1):115-26.
    View on PubMed
  12. Effects of RANKL-Targeted Therapy in Immunity and Cancer. Front Oncol. 2014 Jan 7; 3:329.
    View on PubMed
  13. Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients. J Immunol. 2012 Oct 1; 189(7):3759-66.
    View on PubMed
  14. Unmasking the immune recognition of prostate cancer with CTLA4 blockade. Nat Rev Cancer. 2012 Apr; 12(4):289-97.
    View on PubMed
  15. Dietary zinc deficiency fuels esophageal cancer development by inducing a distinct inflammatory signature. Oncogene. 2012 Oct 18; 31(42):4550-8.
    View on PubMed
  16. A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer. Oncol Rep. 2012 Jan; 27(1):3-9.
    View on PubMed
  17. Immunotherapy for prostate cancer: biology and therapeutic approaches. J Clin Oncol. 2011 Sep 20; 29(27):3677-85.
    View on PubMed
  18. Interplay between CD8a+ dendritic cells and monocytes in response to Listeria monocytogenes infection attenuates T cell responses. PLoS One. 2011; 6(4):e19376.
    View on PubMed
  19. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer. 2011 Sep 15; 117(18):4194-200.
    View on PubMed
  20. Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation. 2010 Dec 27; 90(12):1595-601.
    View on PubMed

Go to UCSF Profiles, powered by CTSI